Integrating such emerging evidence broadens the molecular landscape of lung cancer progression and reinforces the need to evaluate distinct gene signatures—including PECAM1 and ZNF334—across different histological contexts to optimize biomarker-guided strategies for early detection and treatment. Here, ZNF334 is linked to lung cancer.